Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.59 |
| ▸ | USP2 | O75604 | 2/20 | 0.59 |
| ▸ | NAMPT | P43490 | 8/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19158944 | 0.80 | KMT2A (0.60) | CYP3A4NAMPTCYP2C19CYP1A2EPHX2 | |
| SCHEMBL14934448 | 0.78 | EPHX2 (0.76) | CYP3A4CYP2C19EPHX2 | |
| SCHEMBL3021060 | 0.76 | FAAH (0.59) | ALDH1A1CYP3A4CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL3026581 | 0.76 | CYP3A4 (0.49) | ALDH1A1CYP3A4USP2CYP2C19CYP2D6 | |
| SCHEMBL25153745 | 0.75 | HSD17B10 (0.73) | ALDH1A1HSD17B10CYP3A4USP2NAMPT | |
| SCHEMBL14934385 | 0.74 | CYP2D6 (0.60) | ALDH1A1HSD17B10CYP3A4USP2NAMPT | |
| SCHEMBL14934437 | 0.74 | EPHX2 (0.67) | ALDH1A1HSD17B10CYP3A4USP2NAMPT | |
| SCHEMBL3706054 | 0.72 | NAMPT (1.00) | NAMPT | |
| SCHEMBL3702047 | 0.71 | NAMPT (1.00) | NAMPT | |
| SCHEMBL28137409 | 0.70 | KMT2A (0.55) | ALDH1A1CYP3A4USP2CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204224-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC SODIUM CHANNELS | VERNALIS R & D LIMITED (GB) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204224-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC SODIUM CHANNELS | SCN1B, SCN2B, SCN1A | ALDH1A1 823/4885HSD17B10 2036/4885CYP3A4 2928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.